Selinexor Maintenance Therapy for Endometrial Cancer (XPORT-EC-042 Trial)
Trial Summary
The safety of Selinexor, also known as Xpovio or KPT-330, has been evaluated in various clinical trials for different conditions. While specific safety data for endometrial cancer is not detailed in the provided research, Selinexor has been studied in humans, suggesting it has undergone safety assessments in clinical settings.
128910Selinexor is unique because it is an oral drug that works by inhibiting a protein called Exportin 1 (XPO1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus, helping to fight cancer. This mechanism is different from traditional chemotherapy and shows promise as a maintenance therapy after initial treatment, especially in certain genetic subtypes of endometrial cancer.
45679Research shows that Selinexor, when used as a maintenance therapy, significantly extends the time patients with advanced or recurrent endometrial cancer live without the disease getting worse, especially in those with a specific type of genetic makeup (TP53 wild-type).
238910The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants should not have received any systemic anticancer therapy within 3 weeks before starting the trial. It's best to discuss your current medications with the trial team to get specific guidance.